FDA approves Impax’s generic Adderall XR

SILVER SPRING, Md. — Impax Laboratories announced Tuesday that the Food and Drug Administration had approved its generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules. The drug is indicated to treat attention deficit hyperactivity disorder (ADHD). 

 

The drug will be available in 5-, 10-, 15-, 20-, 25- and 30-mg dosage strengths. Branded and generic sales of Adderall XR saw $1.8 billion in annual sales for the 12 months ended November 2015, according to IMS Health.